PROTEUS Patient Summary
The PROTEUS study is a randomized, double-blind, placebo-controlled, phase 3 Study of an investigational drug in subjects with high-risk, localized or locally advanced prostate cancer who are candidates for radical prostatectomy.
As a result, medical researchers recognize the need to prevent reoccurrence of cancer, even after the prostate is removed. In the PROTEUS research study, doctors want to learn more about an investigational medicine that is taken with hormone therapy and given before and after a prostatectomy. They want to see if it is safe and if it is effective and helps prevent cancer from spreading when given to high-risk prostate cancer patients who choose prostate removal surgery as their treatment option.
All participants in this study will receive androgen deprivation therapy (ADT), which is used to reduce male hormone levels and stop them from affecting prostate cancer cells. ADT is commonly given to men for the treatment of prostate cancer. However, it is not currently given to patients before a prostatectomy unless they are in a research study.
Who is eligible to be in the PROTEUS study?
There are other qualifying criteria that your study doctor will be able to discuss with you in more detail. All study-required visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-required travel may be available.
Organization: Janssen Research & Development, LLC
* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.